Company intelligence / Profile preview

Arga Medtech

Epalinges, Vaud, Switzerlandargamedtech.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Arga Medtech has developed a next-generation non-thermal cardiac ablation system using its proprietary CSE™ PFA technology. The company has completed a 42–48 patient first-in-human study in Europe demonstrating high performance in treating atrial fibrillation, with plans to advance to larger US IDE and EU CE Mark studies. The technology aims to improve safety, speed, precision, and long-term outcomes compared to traditional thermal ablation methods

Therapeutic areas: Cardiovascular
Modalities: DevicePulsed Field Ablation system (PFA)Electroporation-based therapy (irreversible electroporation)
Industry: Therapeutic Medical Devices

Partnerships

Gilde HealthcareAdvent Life SciencesEarlybird Venture Capital

Beyond the preview

Go deeper on Arga Medtech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arga Medtech.

Explore the full profile